GlassScriptPhysician profile
Bipasha Mitra
NPI 1831371574
$6,148.05
in general payments reported to CMS, 2019-2025
53 companies · $783 in 2025
The $783 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $866 · 2020: $893 · 2021: $968 · 2022: $823 · 2023: $901 · 2024: $914 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,597.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $778.81 | 2019-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $643.23 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $563.86 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $509.71 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $389.40 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $360.81 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $273.32 | 2020-2025 | Spravato, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.03 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $218.13 | 2021-2025 | Veozah |
| Gilead Sciences, INC. | $205.05 | 2020-2024 | |
| Sanofi-Aventis U.S. LLC | $163.19 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $154.66 | 2019-2024 | Gardasil 9, Gardasil, Vaxelis |
| Takeda Pharmaceuticals U.S.A., INC. | $129.96 | 2019-2025 | Trintellix |
| Lundbeck LLC | $125.94 | 2024-2025 | Vyepti |
| Abbott Laboratories | $100.94 | 2022-2024 | Freestyle Libre 3 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bipasha Mitra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.